Salarius Pharmaceuticals Inc (SLRX) News

Salarius Pharmaceuticals Inc (SLRX): $1.18

-0.03 (-2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SLRX News Items

SLRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SLRX News Highlights

  • SLRX's 30 day story count now stands at 3.
  • Over the past 14 days, the trend for SLRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • FLEX, FET and GLAD are the most mentioned tickers in articles about SLRX.

Latest SLRX News From Around the Web

Below are the latest news stories about Salarius Pharmaceuticals Inc that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually from June 4-8, 2021. “We are very pleased to report that research involving seclidemstat will be the subject of three poster presentations at the 2021 ASCO Annual Meeting,” stated David Arthur, President and CEO of Salarius Pharmaceuticals. “As previously not...

Yahoo | April 19, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning

Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news.

Sarah Smith on InvestorPlace | April 13, 2021

Salarius: Early Stage Nano Cap Targeting Cancer

Photo by koto_feja/E+ via Getty ImagesSalarius Pharma (SLRX) was formed through a reverse merger with the erstwhile Flex Pharma. There's not even a trace of Flex in Salarius, investors will be glad to know, because Flex was a loss-making company formed by a Nobel laureate and his friend and a...

Avisol Capital Partners on Seeking Alpha | April 5, 2021

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ETHOUSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2020. “In 2021, we continue to develop our differentiated LSD1 inhibitor, seclidemstat, for the treatment of cancers with high unmet need. During the fourth quarter of 2020 and through early 2021, Salarius achieved two key objectives that are important for the future of the Company: the completion of the dose-escalation stage of t...

Yahoo | March 18, 2021

Salarius Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Salarius Pharmaceuticals Inc (NASDAQ:SLRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

Yahoo | March 18, 2021

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the closing of its previously announced underwritten public offering of 16,806,722 shares of its common stock, including 2,192,181 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $1.3685 per share. As a result of the underwriters’ over-allotment option exercise, the aggregate gross proceeds to Salarius from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $23 million. “Today’s finan...

Yahoo | March 8, 2021

Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the pricing of an underwritten public offering of 14,614,541 shares of its common stock at a price to the public of $1.3685 per share. The gross proceeds to Salarius from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $20 million. The closing of the offering is expected to take place on or about March 8, 2021, subject to the satisfaction or waiver of customary closing conditions. In addition, Salarius has granted the underwriter a 45-day option to p...

Yahoo | March 4, 2021

Salarius Announces Proposed Public Offering of Common Stock

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering. A shelf registration statement on Form S-3 (File No. 333-231010) relating to the shares was filed with the Securities and Exchange Commission (the “SEC”) and ...

Yahoo | March 3, 2021

Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it will participate in the BIO CEO & Investor Digital Conference taking place Tuesday, February 16, 2021 to Thursday, February 18, 2021. Members of the Salarius management team will be available to participate in one-on-one virtual meetings with registered investors and pharmaceutical companies to discuss Salarius’ business and highlight recent corporate achievements, as well as anticipated milestones in the clinical programs for seclidemstat. Seclidemstat is a reversible LSD1 inhibitor now the subject of two Phase 1/2 clinical trials for Ewing sar...

Yahoo | February 16, 2021

The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASD...

Benzinga | February 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5209 seconds.